Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Heska inks deal with Rapid Diagnostek
As per the deal, Heska will conduct research and development activities and is required to make certain payments to RDI. In addition, Heska holds exclusive rights to sell
As per the deal, Heska will conduct research and development activities and is required to make certain payments to RDI. In addition, Heska holds exclusive rights to sell
The study was intended to investigate the safety, tolerability and pharmacokinetics of 28 days of repeat oral doses of AKB-6548 in a cohort of stage 3 and stage
LOR-2040 is an RNA-targeted drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. The patent covers methods of
The company posted net loss of $176.1m, or $0.87 loss per diluted share, compared to $165.27m, or $0.83 loss per diluted share, for the same period last year.
The study is a Phase III double-blind placebo-controlled trial. Rapid response rates following treatment with certolizumab pegol were achieved across various clinical response measures, including good/moderate EULAR response
The company’s loss from operations was $18.67m, compared to $6.47m for the same period last year. Total operating expenses for the first quarter ended 31 March 2011 were
The iCE 3300GF AA spectrometer is developed for a range of analytical applications across environmental, academic, clinical and food safety laboratories. It features an integrated furnace autosampler for
Under the agreement, ARCA will receive an upfront payment of $2m and is eligible to receive clinical, regulatory and commercial amount totaling $17.5m. ARCA is also currently seeking
According to preclinical studies across multiple animal models, the NAV technology, and in particular NAV rAAV8 vector, targets the photoreceptor layer to preserve vision using gene delivery approaches.
Debio 1036 is an orally available small molecule that antagonizes a key mediator in the inflammation process. The tie up aims at developing inhibitors targeting a fundamental inflammatory